MX2020010085A - Formulaciones que contienen péptidos. - Google Patents
Formulaciones que contienen péptidos.Info
- Publication number
- MX2020010085A MX2020010085A MX2020010085A MX2020010085A MX2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A MX 2020010085 A MX2020010085 A MX 2020010085A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- peptide
- containing formulations
- salt
- glutamic acid
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- 235000013922 glutamic acid Nutrition 0.000 abstract 2
- 239000004220 glutamic acid Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporciona una formulación que comprende ácido glutámico, o una sal de este, y una cantidad eficaz de un péptido. La invención también proporciona un método para preparar la formulación, métodos para tratar una afección usando la formulación y un kit que contiene componentes de la formulación. La invención proporciona además una formulación de liberación sostenida para fármacos que comprenden ácido glutámico, o una sal de este, y una cantidad de un péptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862648746P | 2018-03-27 | 2018-03-27 | |
PCT/US2019/024331 WO2019191264A1 (en) | 2018-03-27 | 2019-03-27 | Peptide-containing formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010085A true MX2020010085A (es) | 2021-01-15 |
Family
ID=66103053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010085A MX2020010085A (es) | 2018-03-27 | 2019-03-27 | Formulaciones que contienen péptidos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11517608B2 (es) |
EP (1) | EP3773627A1 (es) |
JP (1) | JP2021519321A (es) |
KR (1) | KR20200139723A (es) |
CN (1) | CN112040958A (es) |
AU (1) | AU2019243724A1 (es) |
CA (1) | CA3097341A1 (es) |
IL (1) | IL277466A (es) |
MX (1) | MX2020010085A (es) |
TW (1) | TW202002996A (es) |
WO (1) | WO2019191264A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113876929B (zh) * | 2021-11-22 | 2024-02-23 | 中国人民解放军陆军军医大学 | 肽MOTS-c在制备治疗帕金森药物中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001251507A1 (en) | 2000-04-11 | 2001-10-23 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
WO2008153788A2 (en) | 2007-05-30 | 2008-12-18 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
WO2009006359A2 (en) | 2007-06-29 | 2009-01-08 | Centocor, Inc. | Anti- mcp-1 antibodies, compositions, methods and uses |
US7998928B2 (en) | 2007-09-14 | 2011-08-16 | The Regents Of The University Of California | Method of treatment of type-1 diabetes with a humanin analogue |
WO2009135165A2 (en) | 2008-05-01 | 2009-11-05 | The Regents Of The University Of California | Small humanin-like peptides |
WO2012009709A1 (en) | 2010-07-16 | 2012-01-19 | Sudhir Paul | Hiv cd4 binding site based covalent immunogen compositions |
US20130123168A1 (en) | 2011-06-17 | 2013-05-16 | The Regents Of The University Of California | Humanin and humanin-analogues for the management of atherosclerosis |
EP2970410B1 (en) | 2013-03-15 | 2020-01-22 | The Regents of The University of California | Mitochondrial-derived peptide mots3 regulates metabolism and cell survival |
AU2017336440B2 (en) * | 2016-09-28 | 2022-06-02 | Cohbar, Inc. | Therapeutic MOTS-c related peptides |
-
2019
- 2019-03-27 MX MX2020010085A patent/MX2020010085A/es unknown
- 2019-03-27 AU AU2019243724A patent/AU2019243724A1/en not_active Abandoned
- 2019-03-27 TW TW108110719A patent/TW202002996A/zh unknown
- 2019-03-27 KR KR1020207030897A patent/KR20200139723A/ko not_active Application Discontinuation
- 2019-03-27 US US16/981,870 patent/US11517608B2/en active Active
- 2019-03-27 EP EP19717170.5A patent/EP3773627A1/en not_active Withdrawn
- 2019-03-27 CA CA3097341A patent/CA3097341A1/en active Pending
- 2019-03-27 CN CN201980026908.0A patent/CN112040958A/zh active Pending
- 2019-03-27 WO PCT/US2019/024331 patent/WO2019191264A1/en unknown
- 2019-03-27 JP JP2020552234A patent/JP2021519321A/ja not_active Abandoned
-
2020
- 2020-09-21 IL IL277466A patent/IL277466A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202002996A (zh) | 2020-01-16 |
KR20200139723A (ko) | 2020-12-14 |
CN112040958A (zh) | 2020-12-04 |
CA3097341A1 (en) | 2019-10-03 |
JP2021519321A (ja) | 2021-08-10 |
EP3773627A1 (en) | 2021-02-17 |
IL277466A (en) | 2020-11-30 |
US11517608B2 (en) | 2022-12-06 |
AU2019243724A1 (en) | 2020-10-29 |
WO2019191264A1 (en) | 2019-10-03 |
US20210030835A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
MX2022013526A (es) | Degradadores de proteinas y usos de los mismos. | |
MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
MX2019003095A (es) | Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
EA202091372A1 (ru) | Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2 | |
GT201700179A (es) | Formulaciones en polvo nasal para el tratamiento de hipoglicemia | |
AU2017242867A8 (en) | Vortioxetine pamoic acid salt and crystal form thereof | |
TW201625535A (en) | Inhibitors of histone demethylases | |
MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
PT3604304T (pt) | Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase | |
MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
MY172113A (en) | A pharmaceutical composition for neuropathic pain | |
PH12017500436A1 (en) | Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence | |
MX2020010834A (es) | Formulacion solida de mezclas insecticidas. | |
WO2017098051A3 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
MX2021013888A (es) | Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas. | |
EP4311575A3 (en) | Methotrexate for proliferative vitreoretinopathy | |
MX2020010085A (es) | Formulaciones que contienen péptidos. | |
MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
ECSP21079422A (es) | Método para preparar formulaciones de péptidos estables | |
SG11201901617PA (en) | Azole compound ophthalmic preparation |